Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction, Background, & Definition
- Introduction
- A Period of Rapid Developments
- Further Longer-Term Challenges
- Rapid Growth Overall, But Intense Competition
- Moving Into New Applications and Segments
- Customers' Research Models Evolving
- Second-Generation Systems Getting Established
- Background
- Scope and Methodology
- Applications and Definitions
- Types of Samples
- DNA Sequencing Strategies
- DNA Sequencing Chemistries and Techniques
- Sanger Sequencing
- Reversible Terminators
- Single Nucleotide Addition; Pyrosequencing
CHAPTER TWO: SEQUENCER MARKET TRENDS
- Industry and Technology Trends
- Continual Improvements Expand Next-Generation Market
- Spread of Targeted Enrichment, Sequence-Capture Products and Services
- Synergies Appearing Between Life Science Companies' Products
- SNP and Other Experiments Moving to Sequencing for Higher Detail
- Market Fragmenting Into Multiple Applications, Products
- Miniaturization of Sanger and CE Technology
- Rise of Consumer Genomics, Genetic Testing
- Genome Sequencing Trends
- Continued Acceleration in Sequence Output
- Phylogenetic Breakout of Genome Sequencing Projects
- Technologies Used in Genome Projects
- Types of Genome Projects in GOLD Database
- Technologies Used in Genome Projects by Type of Project
- Technologies Used in Genome Projects by Country
- Countries Leading Genome Projects
- Technologies Used in Genome Projects by Institution
- Technologies Used in Genome Projects by Funding Organization
- Technologies Used in Genome Projects by Domain
- Phenotypes of Genomes Being Sequenced
- Diseases / Conditions Associated With Genomes Being Sequenced
- Phylogenetic Breakout of Eukaryotic Genome Projects
- Funding Trends, Genome Centers, Consortia
- Introduction
- Major Sequencing Centers
- Major Funding Sources
- Annual Funding of Genome Projects by Organization
- Funding Relevance of Bacterial Sequencing Projects
- Funding Relevance of Non-Bacterial Genome Project
- NHGRI Annual Funding, Budget, Periodic Strategic Planning
- NHGRI Funds Large-Scale Sequencing Center
- NHGRI White Paper #4: The Future of Genome Sequencing
- The Cancer Genome Atlas Project
- Cancer Sequencing Projec
- FUGE - Functional Genomics in Norway
- National Plant Genome Initiative
- NSF / USDA Microbial Genome Sequencing Programs
- Other Initiatives and Consortia
CHAPTER THREE: DNA SEQUENCER PRODUCTS
- 454 Life Sciences (Branford, CT) / Roche
- Applied Biosystems (Foster City, CA)
- ABI Prism 310 Genetic Analyzer
- ABI Prism 3100-Avant Genetic Analyzer
- Applied Biosystems 3100 Genetic Analyzer
- Applied Biosystems 3130 Genetic Analyzer
- Applied Biosystems 3130xl Genetic Analyzer
- Applied Biosystems 3500 Genetic Analyzer
- Applied Biosystems 3730 DNA Analyzer
- Applied Biosystems 3730xl DNA Analyzer
- SOLiD 3
- Beckman Coulter
- CEQ 8000; CEQ 8800
- GenomeLab GeXP Genetic Analysis System
- Dover Systems (Danaher Motion)
- Polonator G.007
- GE Healthcare
- MegaBACE 500
- MegaBACE 750
- MegaBACE 1000
- MegaBACE 1500
- MegaBACE 4000
- Helicos Biosciences
- Helicos Genetic Analysis System
- Illumina / Solexa
- Illumina Genome Analyzer II
- LI-COR Biosciences (Lincoln, NE)
- Pacific Biosciences
CHAPTER FOUR: DNA SEQUENCER MARKET FORECAST
- Revenues and Forecast
- Current Market (01-08)
- Forecasted Market: ABI as a Market Bellweather
- Growth Indicators
CHAPTER FIVE: COMPETITIVE ANALYSIS OF SEQUENCER MARKET
- Introduction
- Next- and Next-Next-Generation Creating Turbulence
- Capillary Electrophoresis Maintains Large Segment
- Second-, Third-Generation Battle Still Up in the Air
- DNA Sequencer Market Shares
- Features and Strengths of Second-Generation Sequencers
- 454 Life Sciences GS FLX - Strengths / Advantages
- 454 Life Sciences GS FLX - Weaknesses / Disadvantages
- Applied Biosystems SOLiD - Strength / Advantages
- Applied Biosystems SOLiD - Weaknesses / Disadvantages
- Illumina Genome Analyzer - Strength / Advantages
- Illumina Genome Analyzer - Weaknesses / Disadvantages
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
- Patent Interference Between Life Technologies and Pacific Biosciences
- Helicos Appeals European Patent Office Decision on Illumina Patent
- Illumina Files ‘841 Patent Infringement Suit Against Affymetrix
- Affymetrix and Illumina Settle Case Over ‘243, ‘432,
‘531, ‘365, and ‘716
- Applied Biosystems and Illumina Claims and Counter-claims Both Unsuccessful
- Fluidigm and Applied Biosystems Agree to End Case
- Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
- Cepheid and Idaho Technology Settle Dispute Over PCR Patents
- Enzo Biochem Disputes CalTech Sequencing Patents
- Huang v. CalTech
- Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing
Patent Litigation
CHAPTER SEVEN: DEALS
- Significant DNA Sequencing Equipment Deals
CHAPTER EIGHT: CORPORATE PROFILES
- 454 Life Sciences / Roche
- Applied Biosystems / Life Technologies
- Beckman Coulter (Fullerton, CA)
- GE Healthcare Life Sciences
- Helicos Biosciences
- Illumina / Solexa
- LI-COR Biosciences (Lincoln, NE)
CHAPTER NINE: TECHNOLOGIES UNDER DEVELOPMENT
- Introduction
- Human Microbiome Project Awards Funds for Technology Development, Data
Analysis and Ethical Research
- NHGRI Seeks DNA Sequencing Technologies Fit for Routine Laboratory and
Medical Use, August 2008
- Arizona State University, Tempe
- “Sequencing by Recognition”
- Harvard College
- “Electronic Sequencing in Nanopores”
- Oak Ridge National Laboratory / UT Battelle
- “DNA Transport and Sequencing Through a Quadrupole Gate”
- Princeton University
- “Nanogap Detector (Arrays) Inside Nanofluidic Channel for Fast
Real-Time DNA Sequencing”
- University of Arkansas, Fayetteville
- “Exploration of Solid-State Nanopore Reading Labeled Linear DNA
Sequence”
- University of California, San Diego
- “Genome Sequencing by Natural DNA Synthesis on Amplified DNA
Clones”
- University of Pennsylvania, Philadelphia
- “DNA Sequencing Using Nanopore-Nanoelectrode Devices for Sensing
and Manipulation”
- University of Pittsburgh
- “DNA Sequencing at a Stretch”
- Columbia University
- “DNA Sequencing with Reversible dNTP and Cleavable Fluorescent
ddNTP Terminators”
- Foundation for Applied Molecular Evolution, Inc.
- “Near Term Development of Reagents and Enzymes for Genome
Sequencing”
- Illumina
- “Development of a 10Gb Pyrosequencer”
- NHGRI Seeks to Advance Next Generation of Sequencing Technologies, August
2007
- Arizona State University, Tempe
- “Sequencing by Recognition”
- Brown University
- “Hybridization-assisted Nanopore DNA Sequencing”
- Duke University
- “Continuous Sequencing-by-Synthesis Based on a Digital
Microfluidic Platform”
- NABsys, Inc.
- “Hybridization-assisted Nanopore Sequencing”
- North Carolina State University, Raleigh
- “Sequencing DNA by Transverse Electrical Measurements in
Nanochannels”
- UMDNJ-New Jersey Medical School
- “Ribosome-based Single Molecule Method to Acquire Sequence Data
from Genomes”
- University of British Columbia, Vancouver
- “Nanopore Array Force Spectroscopy Chip for Rapid Clinical
Genotyping”
- University of California, Irvine
- “High Throughput Low Cost DNA Sequencing Using Probe Tip
Arrays”
- Columbia University
- “3' -O-Modified Nucleotide Reversible Terminators for
Pyrosequencing”
- “An Integrated System for DNA Sequencing by Synthesis”
- University of New Mexico School of Medicine, Albuquerque
- “Polony Sequencing the Human Genome”
- University of Wisconsin, Madison
- “Sequence Acquisition from Mapped Single DNA Molecules”
- “NHGRI Aims to Make DNA Sequencing Faster, More Cost
Effective”, October 2006
- Arizona State University
- “Fabrication of Universal DNA Nanoarrays for Sequencing by
Hybridization”
- Boston University
- “High-Throughput DNA Sequencing Using Design Polymers and Nanopore
Arrays”
- Case Western Reserve University
- “Large-Scale Nanopore Arrays for DNA Sequencing”
- General Electric Global Research
- “Closed Complex Single Molecule Sequencing”
- Helicos Biosciences
- “High Accuracy Single Molecule DNA Sequencing by Synthesis”
- Lehigh University
- “Force Spectroscopy Platform for Label Free Genome
Sequencing”
- University of California, San Diego
- “Genome Sequencing by Ligation Using Nano-Arrays of Single DNA
Molecules”
- University of North Carolina, Chapel Hill
- “Nanoscale Fluidic Technologies for Rapidly Sequencing Single DNA
Molecules”
- University of Washington, Seattle
- “Engineering MspA for Nanopore Sequencing”
- Baylor College of Medicine, HGSC
- “Ultrafast SBS Method for Large-Scale Human Resequencing”
- Intelligent Bio-Systems
- “High-Throughput DNA Sequencing by Synthesis Platform”
- NHGRI Expands Effort to Revolutionize Sequencing Technologies, August 2005
- Agencourt Personal Genomics [Applied Biosystems / Life Technologies]
- “Bead-Based Polony Sequencing (Supplemental)”
- Network Biosystems
- “$100,000 Genome Using Integrated Microfluidic CE”
- The State University of New York, Stony Brook (SUNY)
- “Ultra High Throughput DNA Sequencing System Based on 2D Monolith
Multi-Capillary Arrays and Nanoliter Reaction Volume”
- Columbia University
- “Modulating Nucleotide Size in DNA for Detection by Nanopore”
- Duke University
- “Droplet-Based Digital Microfluidic Genome Sequencing”
- Harvard University
- “Electronic Sequencing in Nanopores”
- Pacific Biosciences (formerly Nanofluidics)
- “Real-Time Multiplex Single-Molecule DNA Sequencing”
- New York University
- “Haplotype Sequencing Via Single Molecule Hybridization”
- Oxford University and The Scripps Research Institute
- “Single-Molecule DNA Sequencing with Engineered Nanopores”
- University of California, San Diego
- “Massively Parallel Cloning and Sequencing of DNA”
- University of Illinois at Urbana-Champaign
- “Sequencing a DNA Molecule Using a Synthetic Nanopore”
- VisiGen Biotechnologies
- “Real-Time DNA Sequencing”
- NHGRI Funds Next Generation of Sequencing Technologies, October 2004
CHAPTER TEN: CHALLENGES AND STRATEGIC RECOMMENDATIONS
- Market Challenges
- 454' s and Illumina' s Head-Starts Cause Advantages
- Disruptive Technologies, Multiple Variables Creating Unpredictable
Market in Short- and Long-Term
- Biases at Multiple Levels Raise Issues of Standards, Quality Metrics
- Rapidly Changing Technologies Could Fatigue End-Users
- Longer Read Lengths Expected to Steal the Show
- Sequencer Market Slowed by Data Management Bottleneck
- New Entrants Contending With Three Major Life Science Suppliers
- Pharmacogenetics, Consumer Genomics Still Shaking Out
- Strategic Recommendations
- Prepare for Applications Opened by Decreasing Cost
- Balance Risks
- Address Growing International Demand
- User-Friendliness
- Increase Value
- Expanding Routine Industry Segments
- Niche Markets
- Establish Early Connections
- Move Towards Diagnostic Environment Requires Partnering
LIST OF EXHIBITS
CHAPTER TWO: SEQUENCER MARKET TRENDS
- Table 2-1: Completely Sequenced Genomes in GOLD, 1995-2008(Without
Publication, With Publication)
- Figure 2-1: Completely Sequenced Genomes in GOLD, 1999-2008
- Table 2-2: Domains of Completed Genomes in GOLD by Year, 1995-2008
(Archaes' , Bacteria, Eukaryota' )
- Figure 2-2: Domains of Completely Sequenced Genomes in GOLD by Year,
1999-2008 (Archaes' , Bacteria, Eukaryota' )
- Table 2-3: Genome Projects in IMG by Domain, 2005-2008 (Cumulative)
- Figure 2-3: Genome Projects in IMG by Domain, 2005-2008 (Cumulative)
- Table 2-4: Phylogenetic Groups of Sequencing Projects in GOLD, 1998-2008
(Cumulative)
- Figure 2-4: Phylogenetic Groups of Sequencing Projects in GOLD, 1998-2008
(Cumulative)
- Table 2-5: Phylogenetic Distribution of Bacterial Genome Projects, Q1 2007
- Figure 2-5: Phylogenetic Distribution, Bacterial Genome Projects, Q1 2007
- Table 2-6: Phylogenetic Distribution of Bacterial Genome Projects, Q1 2009
- Figure 2-6: Phylogenetic Distribution, Bacterial Genome Projects, Q1 2009
- Table 2-7: Category / Phylogeny of Metagenomics Projects (Cumulative)
- Figure 2-7: Category/Phylogeny of Metagenomics Projects in GOLD, 2008-2009
Cumulative
- Table 2-8: Technology Used in Genome Projects, ' 95-Q1' 09
- Figure 2-8: Sequencer Technology Used in Genome Projects ' 95-Q1' 09
- Table 2-9: Types of Projects in GOLD, ‘95-Q1' 09
- Figure 2-9: Types of Projects in GOLD, ‘95-Q1' 09 (Cumulative)
- Table 2-10: Systems Used in Genome Projects by Type, ' 95-Q1' 09 (Sanger,
Illumina)
- Table 2-11: Systems Used in Genome Projects by Type, ' 95-Q1' 09
- Table 2-12: Systems Used in Genome Projects by Type, ' 95-Q1' 09 Figure
2-10: Systems Used in Genome Projects by Type, ' 95-Q1' 09
- Table 2-13: Systems Used in Genome Projects by Country, ' 95-Q1' 09
- Table 2-14: Systems Used in Genome Projects by Country, ' 95-Q1' 09
- Figure 2-11: Systems Used in Genome Projects by Country, ' 95-Q1' 09
- Table 2-15: Countries Leading Projects, ' 95-Q1' 09
- Figure 2-12: Countries Leading Projects, ' 95-Q1 ' 09
- Table 2-16: Systems Used in Genome Projects by Institute, ' 95-Q1' 09
- Table 2-17: Systems Used in Genome Projects by Inst, ' 95-Q1' 09 Figure
2-13: Systems Used in Genome Projects by Inst, ' 95-Q1' 09
- Table 2-18: Systems Used in Genome Projects by Funding Org., ' 95-Q1' 09
- Table 2-19: Systems Used in Genome Projects by Funding Organization,
' 95-Q1' 09
- Figure 2-14: Systems Used in Genome Projects by Funding Organization,
' 95-Q1' 09
- Table 2-20: System Used in Genome Projects by Domain, ' 95-Q1' 09
- Table 2-21: System Used in Genome Projects by Domain, ' 95-Q1' 09
- Table 2-22: System Used in Genome Projects by Domain, ' 95-Q1' 09
- Figure 2-15: Systems Used in Genome Projects by Domain, ' 95-Q1' 09
- Figure 2-16: Systems Used in Genome Projects by Domain, ' 95-Q1' 09
- Table 2-23: Phenotypes of Projects in GOLD, ' 95-Q1 ' 09
- Figure 2-17: Phenotypes of Projects in GOLD, ' 95-Q1 ' 09
- Table 2-24: Diseases/Conditions Associated with Projects, ' 95-Q1' 09
- Figure 2-18: Diseases/Conditions Associated with Projects, ' 95-Q1 ' 09
- Table 2-25: Eukaryotic Genome Projects in GOLD, ' 07-09
- Figure 2-19: Eukaryotic Genome Projects in GOLD, ' 07-' 09 (Cumulative)
- Table 2-26: Number of Genome Projects by Institute, ' 95- Q1 ' 09
- Figure 2-20 Number of Genome Projects by Institute, ' 95- Q1 ' 09 Cumulative
- Table 2-26 Funding Sources of Genome Projects, ' 95-Q1 ' 09
- Figure 2-21: Funding Sources of Genome Projects, ' 95-Q1 ' 09
- Table 2-26: Funding of Genome Projects by Organization, Q1' 07-Q1' 09
- Figure 2-21: Funding of Genome Projects, 2007-2009 ($M)
- Figure 2-22: Human Genome Project Funding, DOE & NIH ' 90-' 03
- Table 2-27: Relevance of Bacterial Sequencing Projects, ' 95 - Q1 ' 09,
(Cumulative)
- Figure 2-23: Relevance of Bacterial Sequencing Projects, ' 95- Q1 ' 09
(Cumulative)
- Table 2-28: Relevance of Non-Bacterial Sequencing Project, ' 95 - Q1 ' 09,
(Cumulative)
- Figure 2-24: Relevance of Non-Bacterial Sequencing Projects, ' 95- Q1 ' 09
(Cumulative)
- Table 2-29: NHGRI Budget by Year
- Figure 2-25: NHGRI Budget by Year incl. ARRA, 2006-2010
- Table 2-30: 2010 Estimated NHGRI Budget by Mechanism
- Figure 2-26: 2010 Estimated NHGRI Budget by Mechanism (percent)
- Table 2-31: NHGRI Budget by Activity, 2008-2010 (Medical Sequencing,
Genomic Function, Technology Development, Computation Genomics, Large-scale
Sequencing
- Table 2-32: NHGRI Extramural Budget, 2006-2010
- Figure 2-27: NHGRI Extramural Budget by Activity, 2008 Comparable
- Figure 2-28: NHGRI Extramural Budget by Activity, 2009 Estimated
- Figure 2-9: NHGRI Extramural Budget by Activity, 2010 Estimated
- Table 2-33: NHGRI Budget by Mechanism (No. And Amount), FY 2008, FY 2009
and FY2010
- Table 2-34: Large-Scale Sequencing Centers NHGRI Funding, 2004-2006
- Figure 2-10: NHGRI Funded Large-Scale Sequencing Centers ' 04-' 06
- Table 2-34: Large-Scale Sequencing Centers NHGRI Funding by Year, 2007-2008
- Figure 2-11: NHGRI Funded Large-Scale Sequencing Centers ' 07-' 08
- Figure 2-12: Broad Institute Organizational Structure
- Table 2-35: FUGE Funding Recipients
- Table 2-36: Plant Genome Comparative Sequencing Program (PGCSP) Awards,
2007-2008
- Table 2-37: Plant Genome Research Program GEPR, TRMS, and TRPGR Awards,
2007
- Table 2-38: Plant Genome Research Program GEPR, TRMS, and TRPGR Awards,
2008 (Institution, Title, Total Award, Duration)
- Table 2-39: NSF / USDA Microbial Genome Sequencing Program Awards,
2007-2009
- Table 2-40: Other Initiatives and Consortia Supporting Technology
Development, 2009Table 2-41: Other Initiatives and Consortia Performing DNA
Sequencing, 2009
- Table 2-41: Other Initiatives and Consortia Performing DNA Sequencing, 2009
- Table 2-41 (continued): Other Initiatives and Consortia Performing DNA
Sequencing, 2009
CHAPTER THREE: PRODUCTS
- Table 3-1: Key Systems and Technologies Currently in the Market (Company,
Product, Comments)
CHAPTER FOUR: MARKETS
- Table 4-1: Revenues, 2001-2008 DNA Sequencer Equipment
- Table 4-2: Growth Rate, 2001-2008 DNA Sequencer Equipment
- Figure 4-1: Revenues, DNA Sequencer Equipment Market, ' 01-' 08
- Figure 4-2: ABI Sequencing Revenues, Q3 2001 - Q3 2008
- Figure 4-3: ABI Sequencing Revenues, Q4 2004 - Q3 2008
- Figure 4-4: Cost of Sequencing a Genome
- Table 4-3: 2008-2014 DNA Sequencer Equipment Market Forecast
- Figure 4-5: DNA Sequencer Equipment Market Forecast, 2008-2014
- Table 4-4: Growth Rate, 2008-2014 DNA Sequencer Equipment
- Figure 4-6: Growth Rate, DNA Sequencers, 2008-2014
CHAPTER FIVE: COMPETITIVE ANALYSIS OF SEQUENCER MARKET
- Table 5-1: Revenues & Market Shares, DNA Sequencer Systems, 2006 & 2008
- Figure 5-1: Estimated DNA Sequencer Revenues by Company, 2006 & 2008
- Table 5-2: Comparison of Second-Generation Sequencers, 2007
- Table 5-3: Comparison of Second-Generation Sequencers, 2009
CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATION
- Table 6-1: Select Early Sequencing-Related Patents Assigned or Licensed to
Life Technologies / Applied Biosystems
CHAPTER SEVEN: DEALS
- Table 7-1: Significant Deals in the DNA Sequencing Equipment and Services
Market
CHAPTER NINE: TECHNOLOGIES UNDER DEVELOPMENT
- Table 9-1: NIH Human Microbiome Project Technology Development Awards, 2008
- Table 9-2: NHGRI $1000 Genome Grant Awardees, August 2008
- Table 9-3: NHGRI $100,000 Genome Grant Awardees, August 2008
- Table 9-4: NHGRI $1000 Genome Grant Awardees, August 2007
- Table 9-5: NHGRI $100,000 Genome Grant Awardees, August 2007
- Table 9-6: NHGRI $1000 Genome Grant Awardees, October 2006
- Table 9-7: NHGRI $100,000 Genome Grant Awardees, October 2006
- Table 9-8: NHGRI $100,000 Genome Grant Awardees, August 2005
- Table 9-9: NHGRI $1000 Genome Grant Awardees, August 2005
- Table 9-10: NHGRI $100,000 Genome Grant Awardees, October 2004
- Table 9-11: NHGRI $1000 Genome Grant Awardees, October 2004
|
Related Report
|